CMS approves Louisiana subscription-based payment plan for hep C treatments

CMS has approvedLouisiana's plan to supply hepatitis C treatments under a subscription-based payment model, the agency announced June 27.

Under the model, a subsidiary of Gilead Sciences, Asegua Therapeutics, will supply hepatitis C treatments to the state Medicaid program and Department of Corrections in return for subscription-based payments.The state will pay a fixed dollar amount for unlimited access to the medication for five years. 

"The high cost of prescription drugs is one of the greatest challenges in our healthcare system, and Louisiana's innovative approach to leveraging a subscription model to promote access to hepatitis C therapy is a great example of how states can lead in designing solutions," said CMS Administrator Seema Verma.

Copyright © 2022 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Whitepapers

Featured Webinars